143 related articles for article (PubMed ID: 12432213)
1. Repaglinide: a short acting insulin secretagogue for postprandial hyperglycaemia.
Ambavane V; Patil R; Ainapure SS
J Postgrad Med; 2002; 48(3):246-8. PubMed ID: 12432213
[No Abstract] [Full Text] [Related]
2. [Antidiabetic drug at every meal. Repaglinide is especially recommended for slender type 2 diabetic patients].
Landgraf R
MMW Fortschr Med; 2000 Jul; 142(28-29):29-30. PubMed ID: 10959157
[TBL] [Abstract][Full Text] [Related]
3. Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application.
Rosak C; Hofmann U; Paulwitz O
Diabetes Nutr Metab; 2004 Jun; 17(3):137-42. PubMed ID: 15334790
[TBL] [Abstract][Full Text] [Related]
4. Repaglinide for type 2 diabetes mellitus.
Med Lett Drugs Ther; 1998 May; 40(1027):55-6. PubMed ID: 9618664
[No Abstract] [Full Text] [Related]
5. The role of prandial glucose regulation with repaglinide in addressing the problem of hypoglycemia in the treatment of type 2 diabetes.
Owens D
J Assoc Physicians India; 2001 Jan; 49 Spec No():54-61. PubMed ID: 11235607
[No Abstract] [Full Text] [Related]
6. Comments on type 2 diabetes screening and treatment.
Kolaczynski JW
Am Fam Physician; 2000 Jan; 61(1):49-50. PubMed ID: 10643950
[No Abstract] [Full Text] [Related]
7. Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus.
Stephens JW; Bodvarsdottir TB; Wareham K; Prior SL; Bracken RM; Lowe GD; Rumley A; Dunseath G; Luzio S; Deacon CF; Holst JJ; Bain SC
Diabetes Res Clin Pract; 2011 Nov; 94(2):199-206. PubMed ID: 21835486
[TBL] [Abstract][Full Text] [Related]
8. [Therapy of type 2 diabetes. Avoiding postprandial blood glucose peaks!].
MMW Fortschr Med; 2001 Oct; 143(40):55. PubMed ID: 11692849
[No Abstract] [Full Text] [Related]
9. Current understanding regarding the role of repaglinide in post-prandial hyperglycemia.
Menon PS
J Assoc Physicians India; 2001 Jan; 49 Spec No():50-3. PubMed ID: 11235606
[No Abstract] [Full Text] [Related]
10. Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control.
Chisalita SI; Lindström T; Eson Jennersjö P; Paulsson JF; Westermark GT; Olsson AG; Arnqvist HJ
Acta Diabetol; 2009 Mar; 46(1):35-42. PubMed ID: 18777156
[TBL] [Abstract][Full Text] [Related]
11. Repaglinide dose response? A clinician's viewpoint.
Strange P; Goldberg RB
Diabetes Technol Ther; 2000; 2(1):119-21. PubMed ID: 11467310
[No Abstract] [Full Text] [Related]
12. Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.
Raskin P
Diabetes Obes Metab; 2008 Dec; 10(12):1167-77. PubMed ID: 18494804
[TBL] [Abstract][Full Text] [Related]
13. Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide.
Schmitz O; Lund S; Andersen PH; Jønler M; Pørksen N
Diabetes Care; 2002 Feb; 25(2):342-6. PubMed ID: 11815507
[TBL] [Abstract][Full Text] [Related]
14. Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan.
Bakiner O; Ertorer ME; Bozkirli E; Tutuncu NB; Demirag NG
Acta Diabetol; 2009 Mar; 46(1):63-5. PubMed ID: 18825302
[TBL] [Abstract][Full Text] [Related]
15. [symbol: see text] Nateglinide and [symbol: see text] repaglinide for type 2 diabetes?
Drug Ther Bull; 2003 Jul; 41(7):52-4. PubMed ID: 12879789
[TBL] [Abstract][Full Text] [Related]
16. Repaglinide-loaded long-circulating biodegradable nanoparticles: rational approach for the management of type 2 diabetes mellitus.
Jain S; Saraf S
J Diabetes; 2009 Mar; 1(1):29-35. PubMed ID: 20923517
[TBL] [Abstract][Full Text] [Related]
17. Treating type 2 diabetes. When diet and exercise aren't enough, a broad range of medications can help control our blood sugar.
Blackburn GL
Health News; 2004 Aug; 10(8):4-5. PubMed ID: 15551454
[No Abstract] [Full Text] [Related]
18. [Thanks to fast acting insulin analogs, diabetes therapy without hourly schedule].
MMW Fortschr Med; 2002 Nov; 144(46):71. PubMed ID: 12534091
[No Abstract] [Full Text] [Related]
19. Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study.
Jovanovic L; Dailey G; Huang WC; Strange P; Goldstein BJ
J Clin Pharmacol; 2000 Jan; 40(1):49-57. PubMed ID: 10631622
[TBL] [Abstract][Full Text] [Related]
20. Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide.
Yngen M; Ostenson CG; Hjemdahl P; Wallén NH
Diabet Med; 2006 Feb; 23(2):134-40. PubMed ID: 16433710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
